Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723314 | 1.00 | HCRTR2 (0.43) | HCRTR2PTGDR2TBXA2RPTGDRCETP | |
| SCHEMBL27180048 | 1.00 | HCRTR2 (0.43) | HCRTR2PTGDR2TBXA2RPTGDRCETP | |
| SCHEMBL24529380 | 0.82 | HCRTR2 (0.42) | HCRTR2PTGDR2 | |
| SCHEMBL27179403 | 0.81 | HCRTR2 (0.47) | HCRTR2 | |
| SCHEMBL24529495 | 0.81 | HCRTR2 (0.47) | HCRTR2 | |
| SCHEMBL24529532 | 0.79 | HCRTR2 (0.56) | HCRTR2PTGDR2 | |
| SCHEMBL29723599 | 0.79 | HCRTR2 (0.53) | HCRTR2 | |
| SCHEMBL24529498 | 0.79 | HCRTR2 (0.53) | HCRTR2 | |
| SCHEMBL24529503 | 0.79 | HCRTR2 (0.51) | HCRTR2 | |
| SCHEMBL27180841 | 0.79 | HCRTR2 (0.51) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | claimed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HCRTR2 2/4885PTGDR2 863/4885TBXA2R 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.